Scientists from the US have developed antibodies that target Epstein-Barr virus (EBV), a common virus linked to several severe health complications.
On April 16, 2026, the US Court of Appeals for the Federal Circuit issued a precedential decision in Teva Pharmaceuticals International GmbH v.
Detailed price information for ME Therapeutics Holdings Inc. (METX-CN) from The Globe and Mail including charting and trades.
Just two weeks remain before the five-year legal deadline to indict Fauci for denying under oath that he funded “gain of ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
A series of recent physiology studies span from rare disease mechanisms to space-based biomedical advances. Findings include a new mouse model for myofibrillar myopathy type 6 that identifies ...
Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically ...
Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based ...
15d
New clues to hepatitis B species restriction could help build a novel model for studying infection
Some 254 million people live with a chronic hepatitis B (HBV) infection that is often asymptomatic for decades, only to ...
Scientists at Ghent University have created a mouse model that incorporates human versions of the receptors that recognize the fragment crystallizable region of immunoglobulin G, one of the most ...
Understanding human gene function in living organisms has long been hampered by fundamental differences between species. Although mice share most protein-coding genes with humans, their regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results